Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

UNLABELLED The specificity, toxicity and efficacy of lead (212Pb) radioimmunotherapy were evaluated in nude mice bearing the SK-OV-3 human ovarian tumor cell line expressing the HER2/neu proto-oncogene. METHODS The therapeutic agent used was the tumor-specific anti-HER2/neu monoclonal antibody AE1 conjugated to 212Pb, 212Bi being the daughter and thus the source of the alpha-particle and beta emissions. A bifunctional derivative of tetraazacyclododecanetetraacetic acid (p-SCN-Bz-DOTA) was used to couple 212Pb to the anti-HER2/neu monoclonal antibody AE1. The chelating agent did not alter the binding affinity to its antigenic target or the pharmacokinetics and tissue distribution of the AE1 antibody. Toxicity and therapeutic efficacy of 212Pb-AE1 were evaluated in nude mouse ascites or solid tumor models, wherein SK-OV-3 cells were administered i.p. or s.c., respectively. RESULTS The dose-limiting acute toxicity after i.v. administration of 212Pb-AE1 was bone marrow suppression, which was observed at doses above 25 microCi. Therefore, doses of 10 and 20 microCi were used in efficacy trials. The i.p. administration of 212Pb-AE1 3 days after i.p. tumor inoculation led to a significant (P2 = 0.015) prolongation of tumor-free survival. In a second model, i.v. treatment with 212Pb-AE1 3 days after s.c. tumor inoculation prevented subsequent tumor development in all animals treated with 10 or 20 microCi of 212Pb-AE1 (P2 = 0.002 compared to control groups). This efficacy in the adjuvant setting was antibody specific because treatments with equivalently labeled control antibody or unlabeled AE1 antibody or no treatment were less effective. The rate of growth of small (mean tumor volume, 15 mm3) SK-OV-3 tumors was modestly inhibited. However, tumor growth was not inhibited in mice bearing larger (mean tumor volume, 146 mm3) SK-OV-3 tumors by the administration of a single dose of 10 or 20 microCi of 212Pb-AE1. CONCLUSION Lead-212-AE1 as an intact radiolabeled monoclonal antibody may be of only modest value in the therapy of bulky solid tumors due to the short physical half-life of 212Pb and time required to achieve a useful tumor-to-normal tissue ratio of radionuclide after administration. However, the radiolabeled monoclonal antibody may be useful in therapy of tumors in the adjuvant setting. Furthermore, 212Pb may be of value in select situations, including treatment of leukemia, intercavitary therapy or strategies that target vascular endothelial cells of tumors.

[1]  T. Waldmann,et al.  Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. , 1995, Blood.

[2]  M. Brechbiel,et al.  Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies , 1995 .

[3]  L. Presta,et al.  Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. , 1995, Cancer research.

[4]  J. Uhr,et al.  Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. , 1994, Cancer research.

[5]  T. Waldmann,et al.  Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac , 1994 .

[6]  C R King,et al.  Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. , 1994, The Journal of biological chemistry.

[7]  M. Brechbiel,et al.  Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. , 1994, Cancer research.

[8]  J. Humm,et al.  Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. , 1993, International journal of radiation oncology, biology, physics.

[9]  S. Mirzadeh,et al.  The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .

[10]  D. Ring,et al.  In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III. , 1992, Cancer research.

[11]  Y. Watanabe,et al.  A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. , 1992, Cancer research.

[12]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[13]  J. Humm,et al.  Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. , 1992, Radiation research.

[14]  D. Slamon,et al.  Radiolabeled antibody targeting of the HER-2/neu oncoprotein. , 1992, Cancer research.

[15]  M. Brechbiel,et al.  Convenient synthesis of bifunctional tetraaza macrocycles. , 1992, Bioconjugate chemistry.

[16]  L. Presta,et al.  Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene , 1992, The Journal of experimental medicine.

[17]  M. Brechbiel,et al.  Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. , 1992, Cancer research.

[18]  O. Onyekwere,et al.  Selection of reagents for human radioimmunotherapy. , 1992, International journal of radiation oncology, biology, physics.

[19]  A. Ullrich,et al.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[21]  M. Kraus,et al.  Increased erbB-2 gene copies and expression in multiple stages of breast cancer. , 1990, Cancer research.

[22]  S. Mirzadeh,et al.  Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.

[23]  C. Coleman,et al.  Alpha particle radio-immunotherapy: animal models and clinical prospects. , 1989, International journal of radiation oncology, biology, physics.

[24]  T. Waldmann,et al.  Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. , 1989, Cancer research.

[25]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[26]  R. Weichselbaum,et al.  The effect of the alpha-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy. , 1989, Gynecologic oncology.

[27]  H. Huland,et al.  [Monoclonal antibodies in diagnosis and therapy]. , 1989, Immunitat und Infektion.

[28]  Krishan Kumar,et al.  Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .

[29]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[30]  T. Waldmann,et al.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. , 1981, Journal of immunology.

[31]  Applications of tracer theory to protein turnover studies. , 1966, The Journal of nuclear biology and medicine.

[32]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .